Serotonin reuptake inhibition: An update on current research strategies

被引:82
作者
Spinks, D [1 ]
Spinks, G [1 ]
机构
[1] Organon Res Labs Ltd, Dept Med Chem, Newhouse ML1 5SH, Lanark, Scotland
关键词
D O I
10.2174/0929867024606795
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Selective Serotonin reuptake inhibitors (SSRIs) have contributed to the major advances in the treatment of depression and other psychiatric diseases, This review summarises current knowledge concerning the SSRI class of drugs and discusses the importance of secondary pharmacology in the mechanism of action and effectiveness of these drugs. Particular attention is given to the emerging importance of the SSRI 'plus' approach: where the serotonin reuptake receptor inhibition of a drug is supplemented by one or more other receptor interactions either by the same drug or by a combination therapy. This area of research has shed light on the pharmacological mechanisms of SSRI therapy and has the therapeutic usefulness of serotonin reuptake inhibition, especially in the area of depression. There are many new emerging SSRI 'plus' drugs, which address the pharmacological and pharmacokinetic issues of current therapies and these, are discussed in detail.
引用
收藏
页码:799 / 810
页数:12
相关论文
共 112 条
[1]  
AJORTH S, 1996, BEAHV BRAIN RES, V73, P281
[2]   THE EFFICACY OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN DEPRESSION - A METAANALYSIS OF STUDIES AGAINST TRICYCLIC ANTIDEPRESSANTS [J].
ANDERSON, IM ;
TOMENSON, BM .
JOURNAL OF PSYCHOPHARMACOLOGY, 1994, 8 (04) :238-249
[3]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[4]  
ARTIGAS F, 1994, ARCH GEN PSYCHIAT, V51, P248
[5]   How does pindolol improve antidepressant action? [J].
Artigas, F ;
Celada, P ;
Laruelle, M ;
Adell, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (05) :224-228
[6]   5-HT AND ANTIDEPRESSANTS - NEW VIEWS FROM MICRODIALYSIS STUDIES [J].
ARTIGAS, F .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (07) :262-262
[7]  
Barbey JT, 1998, J CLIN PSYCHIAT, V59, P42
[8]  
BARTON CL, 2000, EUROPEAN FORUM NEURO, V10, P214
[9]   EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties [J].
Bartoszyk, GD ;
Hegenbart, R ;
Ziegler, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 322 (2-3) :147-153
[10]  
BERG S, 1998, Patent No. 9913877